EDG-5506 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
113筋ジストロフィー3

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05540860
(ClinicalTrials.gov)
October 24, 20226/9/2022A Study of EDG-5506 in Children With Duchenne Muscular DystrophyA 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part BDuchenne Muscular DystrophyDrug: EDG-5506 Dose 1;Drug: EDG-5506 Dose 2;Drug: EDG-5506 Dose 3;Drug: PlaceboEdgewise Therapeutics, Inc.NULLRecruiting4 Years9 YearsMale27Phase 2United States
2NCT05291091
(ClinicalTrials.gov)
July 6, 202214/3/2022Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (CANYON)A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular DystrophyBecker Muscular DystrophyDrug: EDG-5506 Dose 1;Drug: EDG-5506 Dose 2;Drug: EDG-5506 Dose 3;Drug: EDG-5506 Dose 4;Drug: EDG-5506 Dose 5;Drug: PlaceboEdgewise Therapeutics, Inc.Medpace, Inc.Recruiting12 Years50 YearsMale66Phase 2United States;Netherlands;United Kingdom
3NCT05160415
(ClinicalTrials.gov)
December 28, 20212/12/2021A Study of EDG-5506 in Adult Males With Becker Muscular DystrophyA Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular DystrophyBecker Muscular DystrophyDrug: EDG-5506Edgewise Therapeutics, Inc.Medpace, Inc.Active, not recruiting18 Years55 YearsMale12Phase 1United States